This content is machine translated From chemotherapy to immunotherapy Current system therapy in metastatic non-small cell lung cancer. Detailed molecular diagnosis is now mandatory for non-small cell lung cancer (NSCLC). In the presence of a driver mutation, the corresponding tyrosine kinase inhibitor should be used in the first…
